Synaptic vesicle glycoprotein ligands

Levetiracetam, sold under the brand name Keppra among others, is an antiepileptic drug (medication) used to treat epilepsy. It is used for partial-onset, myoclonic, or tonic–clonic seizures, and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.

Brivaracetam, sold under the brand name Briviact among others, is a chemical analog of levetiracetam, a racetam derivative with anticonvulsant (antiepileptic) properties. It has been approved since 2016. It is marketed by the pharmaceutical company UCB. It is used to treat partial-onset seizures with or without secondary generalisation, in combination with other antiepileptic drugs.

Seletracetam (UCB 44212) is a pyrrolidone-derived drug of the racetam family that is structurally related to levetiracetam (trade name Keppra). It was under development by UCB Pharmaceuticals as a more potent and effective anticonvulsant drug to replace levetiracetam but its development has been halted.